Prospective study of a therapeutic regimen with all‐<i>trans</i> retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study

Imaizumi, Masue; Tawa, Akio; Hanada, Ryoji; Tsuchida, Masahiro; Tabuchi, Ken; Kigasawa, Hisato; Kobayashi, Ryōji; Morimoto, Akira; Nakayama, Hideki; Hamamoto, Kazuko; Kudo, Kazuko; Yabe, Hiromasa; Horibe, Keizo; Tsuchiya, Shigeru; Tsukimoto, Ichiro

doi:10.1111/j.1365-2141.2010.08332.x

Cited by 34 publications

(23 citation statements)

References 35 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this last trial, the addition of ATRA in the consolidation phase also contributed to improve the results (Table 2). 34 Furthermore, the European Leukemia Network recommended including at least one consolidation cycle of high-dose cytarabine for young high-risk patients 1…”

Section: Has Cytarabine At High Doses a Role In The Consolidation Tmentioning

confidence: 99%

Acute Promyelocytic Leukemia (Apl): Comparison Between Children and Adults

Testi¹

2014

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

The outcome of adults and children with Acute Promyelocytic Leukemia (APL) has dramatically changed since the introduction of all trans retinoic acid (ATRA) therapy. Based on the results of several multicenter trials, the current recommendations for the treatment of patients with APL include ATRA and anthracycline-based chemotherapy for the remission induction and consolidation, and ATRA combined with low-dose chemotherapy for maintenance. This has improved the prognosis of APL by increasing the complete remission (CR) rate, actually > 90%, decreasing the induction deaths and by reducing the relapse rate, leading to cure rates nowadays exceeding 80% considering both adults and children.1–9 More recently the combination of ATRA and arsenic trioxide (ATO) as induction and consolidation therapy has been shown to be at least not inferior and possibly superior to ATRA plus chemotherapy in adult patients with APL conventionally defined as non-high risk (Sanz score).10Childhood APL has customarily been treated on adult protocols. Data from several trials have shown that the overall outcome in pediatric APL appears similar to that reported for the adult population; however, some clinical and therapeutic aspects differ in the two cohorts which require some important considerations and treatment adjustments.

show abstract

Section: Has Cytarabine At High Doses a Role In The Consolidation Tmentioning

confidence: 99%

Acute Promyelocytic Leukemia (Apl): Comparison Between Children and Adults

Testi¹

2014

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

“…The Japanese Childhood AML Cooperative Study Group performed a dedicated prospective study of the use of 58 children with de novo APL, between the ages of 11 months and 16 years between 1997 and 2004 [9]. In induction, ATRA at a dose of 45 mg/m 2 was combined with daunorubicin and cytarabine.…”

Section: Cooperative Group Trialsmentioning

confidence: 99%

Acute Promyelocytic Leukemia in Children and Adolescents

Stein

Tallman

2014

Acta Haematol

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL) is a rare subtype of AML characterized by a reciprocal balanced translocation between chromosomes 15 and 17 that fuses the PML gene with the RARα gene and leads to the leukemic phenotype. Although best described in large clinical trials of adults, APL, like other forms of AML, also occurs in children. The positive outcome of children with APL mirrors the dramatic increase in survival seen in adults since the introduction of all-trans retinoic acid (ATRA). In this paper, we review the diagnosis of APL in children as well as large, retrospective, clinical trial data collected on pediatric APL. We also raise management issues and toxicities that are unique to children.

show abstract

“…Creutzig et al188 reported an OS of 89% at 5 years for pediatric patients in consecutive AML–Berlin/Frankfurt/Muenster trials. Imaizumi et al189 reported that patients in the AML99-M3 study achieved an OS of 91% at 7 years.…”

Section: Pediatric Patientsmentioning

confidence: 99%

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives

McCulloch

Brown

Iland

2017

OTT

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) with a unique morphological appearance, associated coagulopathy and canonical balanced translocation of genetic material between chromosomes 15 and 17. APL was first described as a distinct subtype of AML in 1957 by Dr Leif Hillestad who recognized the pattern of an acute leukemia associated with fibrinolysis, hypofibrinogenemia and catastrophic hemorrhage. In the intervening years, the characteristic morphology of APL has been described fully with both classical hypergranular and variant microgranular forms. Both are characterized by a balanced translocation between the long arms of chromosomes 15 and 17, [t(15;17)(q24;q21)], giving rise to a unique fusion gene PML-RARA and an abnormal chimeric transcription factor (PML-RARA), which disrupts normal myeloid differentiation programs. The success of current treatments for APL is in marked contrast to the vast majority of patients with non-promyelocytic AML. The overall prognosis in non-promyelocytic AML is poor, and although there has been an improvement in overall survival in patients aged <60 years, only 30%–40% of younger patients are still alive 5 years after diagnosis. APL therapy has diverged from standard AML therapy through the empirical discovery of two agents that directly target the molecular basis of the disease. The evolution of treatment over the last 4 decades to include all-trans retinoic acid and arsenic trioxide, with chemotherapy limited to patients with high-risk disease, has led to complete remission in 90%–100% of patients in trials and rates of overall survival between 86% and 97%.

show abstract

Prospective study of a therapeutic regimen with all‐trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study

Cited by 34 publications

References 35 publications

Acute Promyelocytic Leukemia (Apl): Comparison Between Children and Adults

Acute Promyelocytic Leukemia (Apl): Comparison Between Children and Adults

Acute Promyelocytic Leukemia in Children and Adolescents

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives

Contact Info

Product

Resources

About